Welcome, visitor! [ Login

Dragon Extends Warrant Exercise Period

News

Dragon Pharmaceuticals Inc. is pleased to announce that the Board of Directors has approved the extension of the Company’s outstanding common share purchase warrants for a period of 2 months. The exercise price remains at $2.50 and the warrants may be exercised until March 1st, 2001.

Dragon Pharmaceuticals is an international biopharmaceutical corporation engaged in the discovery, development and marketing of therapies for infectious diseases, cancer, and cardiovascular diseases. On the basis of its proprietary protein expression technology, Dragon has become one of the world’s lowest cost producers of EPO (Erythropoietin), a blood growth factor used to treat anemia. The 1999 world market for EPO was estimated at US $4.8 billion, with sales expected to grow at a rate of 20 – 25% annually. Dragon is currently in the process of applying its proprietary technology to a number of additional generic drugs.

Top Dragon Pharma Steroids

Dragon Pharma is a pharmaceutical company: Order Enantat 250 – manufacturing and exporting from Europe.

No Tags

1485 total views, 1 today

  

  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics